Humanised anti-interleukin-18 antibody
AssigneeGlaxo Group Limited
InventorsJonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
Life of this patent
Estimating the term…
Abstract
The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
Claims7
A humanised anti-interleukin-18 antibody comprising a heavy chain and light chain comprising the following complementarity determining regions (CDRs):
- CDRH1:
- SEQ ID NO:1;
- CDRH2:
- SEQ ID NO:2;
- CDRH3:
- SEQ ID NO:3;
- CDRL1:
- SEQ ID NO:4;
- CDRL2:
- SEQ ID NO:5;
- and
- CDRL3:
- SEQ ID NO:6,
- wherein said antibody comprises a heavy chain selected from the group consisting of:
- SEQ ID NO:
- 9, SEQ ID NO:
- 17, and SEQ ID NO:
- 21;
- and a light chain selected from the group consisting of:
- SEQ ID NO:
- 13 and SEQ ID NO:
- 29.
A humanised anti-interleukin-18 antibody comprising a heavy chain comprising SEQ ID NO:9 and a light chain comprising SEQ ID NO:13.
A humanised anti-interleukin-18 antibody, wherein said antibody comprises a heavy chain selected from the group consisting of:
- SEQ ID NO:9, SEQ ID NO:17, and SEQ ID NO:21.
A humanised anti-interleukin-18 antibody, wherein said antibody comprises a light chain selected from the group consisting of:
- SEQ ID NO:13 and SEQ ID NO:29.
Dependencies are inferred from the claim text.